224 related articles for article (PubMed ID: 34205249)
1. Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity.
Ghanem SS; Fayed HS; Zhu Q; Lu JH; Vaikath NN; Ponraj J; Mansour S; El-Agnaf OMA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205249
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts.
Ardah MT; Ghanem SS; Abdulla SA; Lv G; Emara MM; Paleologou KE; Vaikath NN; Lu JH; Li M; Vekrellis K; Eliezer D; El-Agnaf OMA
BMC Complement Med Ther; 2020 Mar; 20(1):73. PubMed ID: 32143619
[TBL] [Abstract][Full Text] [Related]
3. The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple α-synuclein strains.
Peña-Díaz S; Pujols J; Vasili E; Pinheiro F; Santos J; Manglano-Artuñedo Z; Outeiro TF; Ventura S
J Biol Chem; 2022 May; 298(5):101902. PubMed ID: 35390347
[TBL] [Abstract][Full Text] [Related]
4. Cryo-EM structure of amyloid fibril formed by α-synuclein hereditary A53E mutation reveals a distinct protofilament interface.
Sun C; Zhou K; DePaola P; Shin WS; Hillyer T; Sawaya MR; Zhu R; Peng C; Zhou ZH; Jiang L
J Biol Chem; 2023 Apr; 299(4):104566. PubMed ID: 36871760
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
[TBL] [Abstract][Full Text] [Related]
6. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
7. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
8. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils.
Hmila I; Sudhakaran IP; Ghanem SS; Vaikath NN; Poggiolini I; Abdesselem H; El-Agnaf OMA
ACS Chem Neurosci; 2022 Dec; 13(23):3330-3341. PubMed ID: 36348612
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.
Xu Y; Zhang Y; Quan Z; Wong W; Guo J; Zhang R; Yang Q; Dai R; McGeer PL; Qing H
Neurochem Res; 2016 Oct; 41(10):2788-2796. PubMed ID: 27364962
[TBL] [Abstract][Full Text] [Related]
11. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
[TBL] [Abstract][Full Text] [Related]
12. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
13. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
Bickle L; Hopwood JJ; Karageorgos L
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
[TBL] [Abstract][Full Text] [Related]
14. Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium.
Nahass GR; Sun Y; Xu Y; Batchelor M; Reilly M; Benilova I; Kedia N; Spehar K; Sobott F; Sessions RB; Caughey B; Radford SE; Jat PS; Collinge J; Bieschke J
J Mol Biol; 2021 Apr; 433(8):166878. PubMed ID: 33610557
[TBL] [Abstract][Full Text] [Related]
15. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
[TBL] [Abstract][Full Text] [Related]
17. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
18. Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils.
Murray KA; Hu CJ; Pan H; Lu J; Abskharon R; Bowler JT; Rosenberg GM; Williams CK; Elezi G; Balbirnie M; Faull KF; Vinters HV; Seidler PM; Eisenberg DS
Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2217835120. PubMed ID: 36757890
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.
Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI
J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion.
Ham S; Yun SP; Kim H; Kim D; Seo BA; Kim H; Shin JY; Dar MA; Lee GH; Lee YI; Kim D; Kim S; Kweon HS; Shin JH; Ko HS; Lee Y
Sci Transl Med; 2020 Nov; 12(569):. PubMed ID: 33177178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
